article thumbnail

GrayMatters Health Expands FDA-Cleared PTSD Treatment Expands to US Clinics

HIT Consultant

– As the first FDA-cleared self-neuromodulation device for post-traumatic stress disorder (PTSD), Prism for PTSD™ offers a new approach to managing this debilitating condition. Broad Impact: A new analysis presented at the International Society for Traumatic Stress Studies showed significant effects across all PTSD symptom clusters.

FDA 97
article thumbnail

Red Dye No. 3 and the Delaney Clause: A Relic of the Past or a Necessary Safety Measure?

Bill of Health

Food and Drug Administration (FDA) banned the use of Red Dye No. Food and Drug Administration (FDA) banned the use of Red Dye No. The Regulatory Framework for Food and Color Additives FDA regulates the U.S. While a seemingly innocuous phrase, this language has come to haunt FDA. 15, 2025, the U.S. 15, 2025, the U.S.

FDA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Brief Quantum Medicine Policy Guide

Bill of Health

Quantum-driven healthcare innovations present quantum-specific regulatory challenges, discussed in more detail below. US Legal Requirements for Quantum-Powered Medical Devices In the United States, some quantum-powered medical devices may be governed under the existing FDA regulatory framework.

FDA 182
article thumbnail

Public Health Product Hops

Bill of Health

On a panel together, we each presented on topics relating to product hopping, but from very different perspectives. In each scenario, public health considerations drove the product switches and the FDA actively encouraged the development of reformulated products.

article thumbnail

FDA releases draft guidance for Breakthrough Devices Program aimed at health inequities

Mobi Health News

When determining approval for Breakthrough Device designation, the FDA will consider whether the device addresses present health inequities.

FDA 126
article thumbnail

FDA takes first steps toward new guidance for adaptive medical AI

Mobi Health News

An exploratory whitepaper dropped yesterday lays out a framework that the FDA hopes to present in a future draft guidance.

FDA 111
article thumbnail

FDA Selects Ontada to Investigate Rare Cancers Treated in US Community Oncology Setting

HIT Consultant

Food and Drug Administration (FDA) to advance the use of real-world data (RWD) in the U.S. Study Goals & Objectives The goal of the study is to better understand how patients with rare cancers present and are treated to inform drug development for life sciences companies and the FDA. community oncology setting.

FDA 98